ELIXIRGEN
RegisteredCombined Mark
Never miss important updates for ELIXIRGEN
Get alerts when status changes, similar marks are filed, or renewal deadlines approach
Ownership
ET
Address
855 N. Wolfe St., Suite 624
Baltimore, MD 21205
Critical Dates
First Use Date
May 19, 2016
Filing Date
Oct 1, 2016
Registration Date
Oct 31, 2017
Mark Descriptions
Goods
Class 5
pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis...
Services
Class 42
pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis...
Mark Elements
Text Mark
ELIXIRGEN
Category
Trademark
Standard Characters
No
Color Claim
No
Drawing/Image Description
The mark consists of a stylized triangular geometric shape and the stylized wording "ELIXIRGEN".
Design Search Codes
260528
Trademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
No documents found for this trademark.